Oncotarget

Research Papers:

Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma

Pei-Yu Huang, Shan-Shan Guo, Yu Zhang, Jia-Bin Lu, Qiu-Yan Chen, Lin-Quan Tang, Lu Zhang, Li-Ting Liu, Li Zhang _ and Hai-Qiang Mai

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:13060-13068. https://doi.org/10.18632/oncotarget.7421

Metrics: PDF 2062 views  |   HTML 2870 views  |   ?  


Abstract

Pei-Yu Huang1,2,*, Shan-Shan Guo1,2,*, Yu Zhang1,3,*, Jia-Bin Lu1,3, Qiu-Yan Chen1,2, Lin-Quan Tang1,2, Lu Zhang1,2, Li-Ting Liu1,2, Li Zhang1,4, Hai-Qiang Mai1,2

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

2Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China

3Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China

4Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

*These authors contributed equally to this work

Correspondence to:

Li Zhang, e-mail: [email protected]

Hai-Qiang Mai, e-mail: [email protected]

Keywords: CTLA-4, CD28, nasopharyngeal carcinoma, immunohistochemistry, prognostic factor

Received: July 05, 2015     Accepted: January 26, 2016     Published: February 16, 2016

ABSTRACT

The expression levels of CTLA-4 and CD28 were analyzed in 191 nasopharyngeal carcinoma (NPC) patients diagnosed and treated at our hospital between January 2010 and November 2011. The 3-year overall survival (OS) rate (91.4% vs. 81.2%,p = 0.043), failure-free survival (FFS) rate (82.8% vs. 68.0%, p = 0.009) and distant failure-free survival (D-FFS) rate (85.8% vs. 72.3%, p = 0.006) in the low tumor CTLA-4 expression group was higher than in the high tumor CTLA-4 group. There were no differences between the locoregional failure-free survival (LR-FFS) rates in the high and low tumor CTLA-4 expression groups. Moreover, no differences in the OS, FFS, D-FFS, or LR-FFS were observed between the groups with high and low lymphocyte CTLA-4 levels, high and low tumor CD28 levels, or high and low lymphocyte CD28 levels. Cox regression analysis confirmed the prognostic value of tumor CTLA-4 expression, particularly for D-FFS, in NPC patients (p = 0.044). NPC patients with high tumor CTLA-4 expression had a poorer prognosis than those with low expression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7421